カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のRNAポリメラーゼ阻害剤市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global RNA Polymerase Inhibitor Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
	■ 発行会社/調査会社：GlobalInfoResearch ■ 商品コード：GIR22NO19608 ■ 発行日：2022年11月（※2025年版があります。お問い合わせください。） ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：100 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（注文後2-3日）

■ 販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,480 ⇒換算￥528,960	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,220 ⇒換算￥793,440	見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）	USD6,960 ⇒換算￥1,057,920	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[世界のRNAポリメラーゼ阻害剤市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら

*** レポート概要（サマリー）***

RNAポリメラーゼ阻害剤市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のRNAポリメラーゼ阻害剤の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

RNAポリメラーゼ阻害剤市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・ベリパリブ、ルカパリブ、タラゾパリブ、ニラパリブ、その他

用途別セグメントは次のように区分されます。
・病院調剤薬局、小売調剤薬局、オンライン調剤薬局

世界のRNAポリメラーゼ阻害剤市場の主要な市場プレーヤーは以下のとおりです。
・Johnson & Johnson、AstraZeneca、AbbVie、Bristol Myers Squibb、Repare Therapeutics、Merck、Genentech、Artios Pharma、Pfizer、Sierra Oncology、GlaxoSmithKline、Clovis Oncology、Karyopharm Therapeutics

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、RNAポリメラーゼ阻害剤製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なRNAポリメラーゼ阻害剤メーカーの企業概要、2019年～2022年までのRNAポリメラーゼ阻害剤の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なRNAポリメラーゼ阻害剤メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別RNAポリメラーゼ阻害剤の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのRNAポリメラーゼ阻害剤の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのRNAポリメラーゼ阻害剤市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびRNAポリメラーゼ阻害剤の産業チェーンを掲載しています。
・第13、14、15章では、RNAポリメラーゼ阻害剤の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- RNAポリメラーゼ阻害剤の概要
- 種類別分析（2017年vs2021年vs2028年）：ベリパリブ、ルカパリブ、タラゾパリブ、ニラパリブ、その他
- 用途別分析（2017年vs2021年vs2028年）：病院調剤薬局、小売調剤薬局、オンライン調剤薬局
- 世界のRNAポリメラーゼ阻害剤市場規模・予測
- 世界のRNAポリメラーゼ阻害剤生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Johnson & Johnson、AstraZeneca、AbbVie、Bristol Myers Squibb、Repare Therapeutics、Merck、Genentech、Artios Pharma、Pfizer、Sierra Oncology、GlaxoSmithKline、Clovis Oncology、Karyopharm Therapeutics
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：ベリパリブ、ルカパリブ、タラゾパリブ、ニラパリブ、その他
・用途別分析2017年-2028年：病院調剤薬局、小売調剤薬局、オンライン調剤薬局
・RNAポリメラーゼ阻害剤の北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・RNAポリメラーゼ阻害剤のヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・RNAポリメラーゼ阻害剤のアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・RNAポリメラーゼ阻害剤の南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・RNAポリメラーゼ阻害剤の中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The RNA Polymerase Inhibitor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global RNA Polymerase Inhibitor market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital Pharmacies accounting for % of the RNA Polymerase Inhibitor global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Veliparib segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of RNA Polymerase Inhibitor include Johnson & Johnson, AstraZeneca, AbbVie, Bristol Myers Squibb, and Repare Therapeutics, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
RNA Polymerase Inhibitor market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Veliparib
Rucaparib
Talazoparib
Niraparib
Others
Market segment by Application can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
The key market players for global RNA Polymerase Inhibitor market are listed below:
Johnson & Johnson
AstraZeneca
AbbVie
Bristol Myers Squibb
Repare Therapeutics
Merck
Genentech
Artios Pharma
Pfizer
Sierra Oncology
GlaxoSmithKline
Clovis Oncology
Karyopharm Therapeutics
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe RNA Polymerase Inhibitor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of RNA Polymerase Inhibitor, with price, sales, revenue and global market share of RNA Polymerase Inhibitor from 2019 to 2022.
Chapter 3, the RNA Polymerase Inhibitor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the RNA Polymerase Inhibitor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and RNA Polymerase Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of RNA Polymerase Inhibitor.
Chapter 13, 14, and 15, to describe RNA Polymerase Inhibitor sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 RNA Polymerase Inhibitor Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global RNA Polymerase Inhibitor Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Veliparib
1.2.3 Rucaparib
1.2.4 Talazoparib
1.2.5 Niraparib
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global RNA Polymerase Inhibitor Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global RNA Polymerase Inhibitor Market Size & Forecast
1.4.1 Global RNA Polymerase Inhibitor Sales in Value (2017 & 2021 & 2028)
1.4.2 Global RNA Polymerase Inhibitor Sales in Volume (2017-2028)
1.4.3 Global RNA Polymerase Inhibitor Price (2017-2028)
1.5 Global RNA Polymerase Inhibitor Production Capacity Analysis
1.5.1 Global RNA Polymerase Inhibitor Total Production Capacity (2017-2028)
1.5.2 Global RNA Polymerase Inhibitor Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 RNA Polymerase Inhibitor Market Drivers
1.6.2 RNA Polymerase Inhibitor Market Restraints
1.6.3 RNA Polymerase Inhibitor Trends Analysis
2 Manufacturers Profiles
2.1 Johnson & Johnson
2.1.1 Johnson & Johnson Details
2.1.2 Johnson & Johnson Major Business
2.1.3 Johnson & Johnson RNA Polymerase Inhibitor Product and Services
2.1.4 Johnson & Johnson RNA Polymerase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business
2.2.3 AstraZeneca RNA Polymerase Inhibitor Product and Services
2.2.4 AstraZeneca RNA Polymerase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 AbbVie
2.3.1 AbbVie Details
2.3.2 AbbVie Major Business
2.3.3 AbbVie RNA Polymerase Inhibitor Product and Services
2.3.4 AbbVie RNA Polymerase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Bristol Myers Squibb
2.4.1 Bristol Myers Squibb Details
2.4.2 Bristol Myers Squibb Major Business
2.4.3 Bristol Myers Squibb RNA Polymerase Inhibitor Product and Services
2.4.4 Bristol Myers Squibb RNA Polymerase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Repare Therapeutics
2.5.1 Repare Therapeutics Details
2.5.2 Repare Therapeutics Major Business
2.5.3 Repare Therapeutics RNA Polymerase Inhibitor Product and Services
2.5.4 Repare Therapeutics RNA Polymerase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business
2.6.3 Merck RNA Polymerase Inhibitor Product and Services
2.6.4 Merck RNA Polymerase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Genentech
2.7.1 Genentech Details
2.7.2 Genentech Major Business
2.7.3 Genentech RNA Polymerase Inhibitor Product and Services
2.7.4 Genentech RNA Polymerase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Artios Pharma
2.8.1 Artios Pharma Details
2.8.2 Artios Pharma Major Business
2.8.3 Artios Pharma RNA Polymerase Inhibitor Product and Services
2.8.4 Artios Pharma RNA Polymerase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer RNA Polymerase Inhibitor Product and Services
2.9.4 Pfizer RNA Polymerase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Sierra Oncology
2.10.1 Sierra Oncology Details
2.10.2 Sierra Oncology Major Business
2.10.3 Sierra Oncology RNA Polymerase Inhibitor Product and Services
2.10.4 Sierra Oncology RNA Polymerase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 GlaxoSmithKline
2.11.1 GlaxoSmithKline Details
2.11.2 GlaxoSmithKline Major Business
2.11.3 GlaxoSmithKline RNA Polymerase Inhibitor Product and Services
2.11.4 GlaxoSmithKline RNA Polymerase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Clovis Oncology
2.12.1 Clovis Oncology Details
2.12.2 Clovis Oncology Major Business
2.12.3 Clovis Oncology RNA Polymerase Inhibitor Product and Services
2.12.4 Clovis Oncology RNA Polymerase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Karyopharm Therapeutics
2.13.1 Karyopharm Therapeutics Details
2.13.2 Karyopharm Therapeutics Major Business
2.13.3 Karyopharm Therapeutics RNA Polymerase Inhibitor Product and Services
2.13.4 Karyopharm Therapeutics RNA Polymerase Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 RNA Polymerase Inhibitor Breakdown Data by Manufacturer
3.1 Global RNA Polymerase Inhibitor Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global RNA Polymerase Inhibitor Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in RNA Polymerase Inhibitor
3.4 Market Concentration Rate
3.4.1 Top 3 RNA Polymerase Inhibitor Manufacturer Market Share in 2021
3.4.2 Top 6 RNA Polymerase Inhibitor Manufacturer Market Share in 2021
3.5 Global RNA Polymerase Inhibitor Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and RNA Polymerase Inhibitor Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global RNA Polymerase Inhibitor Market Size by Region
4.1.1 Global RNA Polymerase Inhibitor Sales in Volume by Region (2017-2028)
4.1.2 Global RNA Polymerase Inhibitor Revenue by Region (2017-2028)
4.2 North America RNA Polymerase Inhibitor Revenue (2017-2028)
4.3 Europe RNA Polymerase Inhibitor Revenue (2017-2028)
4.4 Asia-Pacific RNA Polymerase Inhibitor Revenue (2017-2028)
4.5 South America RNA Polymerase Inhibitor Revenue (2017-2028)
4.6 Middle East and Africa RNA Polymerase Inhibitor Revenue (2017-2028)
5 Market Segment by Type
5.1 Global RNA Polymerase Inhibitor Sales in Volume by Type (2017-2028)
5.2 Global RNA Polymerase Inhibitor Revenue by Type (2017-2028)
5.3 Global RNA Polymerase Inhibitor Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global RNA Polymerase Inhibitor Sales in Volume by Application (2017-2028)
6.2 Global RNA Polymerase Inhibitor Revenue by Application (2017-2028)
6.3 Global RNA Polymerase Inhibitor Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America RNA Polymerase Inhibitor Sales by Type (2017-2028)
7.2 North America RNA Polymerase Inhibitor Sales by Application (2017-2028)
7.3 North America RNA Polymerase Inhibitor Market Size by Country
7.3.1 North America RNA Polymerase Inhibitor Sales in Volume by Country (2017-2028)
7.3.2 North America RNA Polymerase Inhibitor Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe RNA Polymerase Inhibitor Sales by Type (2017-2028)
8.2 Europe RNA Polymerase Inhibitor Sales by Application (2017-2028)
8.3 Europe RNA Polymerase Inhibitor Market Size by Country
8.3.1 Europe RNA Polymerase Inhibitor Sales in Volume by Country (2017-2028)
8.3.2 Europe RNA Polymerase Inhibitor Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific RNA Polymerase Inhibitor Sales by Type (2017-2028)
9.2 Asia-Pacific RNA Polymerase Inhibitor Sales by Application (2017-2028)
9.3 Asia-Pacific RNA Polymerase Inhibitor Market Size by Region
9.3.1 Asia-Pacific RNA Polymerase Inhibitor Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific RNA Polymerase Inhibitor Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America RNA Polymerase Inhibitor Sales by Type (2017-2028)
10.2 South America RNA Polymerase Inhibitor Sales by Application (2017-2028)
10.3 South America RNA Polymerase Inhibitor Market Size by Country
10.3.1 South America RNA Polymerase Inhibitor Sales in Volume by Country (2017-2028)
10.3.2 South America RNA Polymerase Inhibitor Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa RNA Polymerase Inhibitor Sales by Type (2017-2028)
11.2 Middle East & Africa RNA Polymerase Inhibitor Sales by Application (2017-2028)
11.3 Middle East & Africa RNA Polymerase Inhibitor Market Size by Country
11.3.1 Middle East & Africa RNA Polymerase Inhibitor Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa RNA Polymerase Inhibitor Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of RNA Polymerase Inhibitor and Key Manufacturers
12.2 Manufacturing Costs Percentage of RNA Polymerase Inhibitor
12.3 RNA Polymerase Inhibitor Production Process
12.4 RNA Polymerase Inhibitor Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 RNA Polymerase Inhibitor Typical Distributors
13.3 RNA Polymerase Inhibitor Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global RNA Polymerase Inhibitor Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global RNA Polymerase Inhibitor Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 4. Johnson & Johnson Major Business
Table 5. Johnson & Johnson RNA Polymerase Inhibitor Product and Services
Table 6. Johnson & Johnson RNA Polymerase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 8. AstraZeneca Major Business
Table 9. AstraZeneca RNA Polymerase Inhibitor Product and Services
Table 10. AstraZeneca RNA Polymerase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. AbbVie Basic Information, Manufacturing Base and Competitors
Table 12. AbbVie Major Business
Table 13. AbbVie RNA Polymerase Inhibitor Product and Services
Table 14. AbbVie RNA Polymerase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 16. Bristol Myers Squibb Major Business
Table 17. Bristol Myers Squibb RNA Polymerase Inhibitor Product and Services
Table 18. Bristol Myers Squibb RNA Polymerase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Repare Therapeutics Basic Information, Manufacturing Base and Competitors
Table 20. Repare Therapeutics Major Business
Table 21. Repare Therapeutics RNA Polymerase Inhibitor Product and Services
Table 22. Repare Therapeutics RNA Polymerase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Merck Basic Information, Manufacturing Base and Competitors
Table 24. Merck Major Business
Table 25. Merck RNA Polymerase Inhibitor Product and Services
Table 26. Merck RNA Polymerase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Genentech Basic Information, Manufacturing Base and Competitors
Table 28. Genentech Major Business
Table 29. Genentech RNA Polymerase Inhibitor Product and Services
Table 30. Genentech RNA Polymerase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Artios Pharma Basic Information, Manufacturing Base and Competitors
Table 32. Artios Pharma Major Business
Table 33. Artios Pharma RNA Polymerase Inhibitor Product and Services
Table 34. Artios Pharma RNA Polymerase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Pfizer Basic Information, Manufacturing Base and Competitors
Table 36. Pfizer Major Business
Table 37. Pfizer RNA Polymerase Inhibitor Product and Services
Table 38. Pfizer RNA Polymerase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Sierra Oncology Basic Information, Manufacturing Base and Competitors
Table 40. Sierra Oncology Major Business
Table 41. Sierra Oncology RNA Polymerase Inhibitor Product and Services
Table 42. Sierra Oncology RNA Polymerase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 44. GlaxoSmithKline Major Business
Table 45. GlaxoSmithKline RNA Polymerase Inhibitor Product and Services
Table 46. GlaxoSmithKline RNA Polymerase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Clovis Oncology Basic Information, Manufacturing Base and Competitors
Table 48. Clovis Oncology Major Business
Table 49. Clovis Oncology RNA Polymerase Inhibitor Product and Services
Table 50. Clovis Oncology RNA Polymerase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Karyopharm Therapeutics Basic Information, Manufacturing Base and Competitors
Table 52. Karyopharm Therapeutics Major Business
Table 53. Karyopharm Therapeutics RNA Polymerase Inhibitor Product and Services
Table 54. Karyopharm Therapeutics RNA Polymerase Inhibitor Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 55. Global RNA Polymerase Inhibitor Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 56. Global RNA Polymerase Inhibitor Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 57. Market Position of Manufacturers in RNA Polymerase Inhibitor, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 58. Global RNA Polymerase Inhibitor Production Capacity by Company, (K Units): 2020 VS 2021
Table 59. Head Office and RNA Polymerase Inhibitor Production Site of Key Manufacturer
Table 60. RNA Polymerase Inhibitor New Entrant and Capacity Expansion Plans
Table 61. RNA Polymerase Inhibitor Mergers & Acquisitions in the Past Five Years
Table 62. Global RNA Polymerase Inhibitor Sales by Region (2017-2022) & (K Units)
Table 63. Global RNA Polymerase Inhibitor Sales by Region (2023-2028) & (K Units)
Table 64. Global RNA Polymerase Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 65. Global RNA Polymerase Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 66. Global RNA Polymerase Inhibitor Sales by Type (2017-2022) & (K Units)
Table 67. Global RNA Polymerase Inhibitor Sales by Type (2023-2028) & (K Units)
Table 68. Global RNA Polymerase Inhibitor Revenue by Type (2017-2022) & (USD Million)
Table 69. Global RNA Polymerase Inhibitor Revenue by Type (2023-2028) & (USD Million)
Table 70. Global RNA Polymerase Inhibitor Price by Type (2017-2022) & (US$/Unit)
Table 71. Global RNA Polymerase Inhibitor Price by Type (2023-2028) & (US$/Unit)
Table 72. Global RNA Polymerase Inhibitor Sales by Application (2017-2022) & (K Units)
Table 73. Global RNA Polymerase Inhibitor Sales by Application (2023-2028) & (K Units)
Table 74. Global RNA Polymerase Inhibitor Revenue by Application (2017-2022) & (USD Million)
Table 75. Global RNA Polymerase Inhibitor Revenue by Application (2023-2028) & (USD Million)
Table 76. Global RNA Polymerase Inhibitor Price by Application (2017-2022) & (US$/Unit)
Table 77. Global RNA Polymerase Inhibitor Price by Application (2023-2028) & (US$/Unit)
Table 78. North America RNA Polymerase Inhibitor Sales by Country (2017-2022) & (K Units)
Table 79. North America RNA Polymerase Inhibitor Sales by Country (2023-2028) & (K Units)
Table 80. North America RNA Polymerase Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 81. North America RNA Polymerase Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 82. North America RNA Polymerase Inhibitor Sales by Type (2017-2022) & (K Units)
Table 83. North America RNA Polymerase Inhibitor Sales by Type (2023-2028) & (K Units)
Table 84. North America RNA Polymerase Inhibitor Sales by Application (2017-2022) & (K Units)
Table 85. North America RNA Polymerase Inhibitor Sales by Application (2023-2028) & (K Units)
Table 86. Europe RNA Polymerase Inhibitor Sales by Country (2017-2022) & (K Units)
Table 87. Europe RNA Polymerase Inhibitor Sales by Country (2023-2028) & (K Units)
Table 88. Europe RNA Polymerase Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 89. Europe RNA Polymerase Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 90. Europe RNA Polymerase Inhibitor Sales by Type (2017-2022) & (K Units)
Table 91. Europe RNA Polymerase Inhibitor Sales by Type (2023-2028) & (K Units)
Table 92. Europe RNA Polymerase Inhibitor Sales by Application (2017-2022) & (K Units)
Table 93. Europe RNA Polymerase Inhibitor Sales by Application (2023-2028) & (K Units)
Table 94. Asia-Pacific RNA Polymerase Inhibitor Sales by Region (2017-2022) & (K Units)
Table 95. Asia-Pacific RNA Polymerase Inhibitor Sales by Region (2023-2028) & (K Units)
Table 96. Asia-Pacific RNA Polymerase Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 97. Asia-Pacific RNA Polymerase Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 98. Asia-Pacific RNA Polymerase Inhibitor Sales by Type (2017-2022) & (K Units)
Table 99. Asia-Pacific RNA Polymerase Inhibitor Sales by Type (2023-2028) & (K Units)
Table 100. Asia-Pacific RNA Polymerase Inhibitor Sales by Application (2017-2022) & (K Units)
Table 101. Asia-Pacific RNA Polymerase Inhibitor Sales by Application (2023-2028) & (K Units)
Table 102. South America RNA Polymerase Inhibitor Sales by Country (2017-2022) & (K Units)
Table 103. South America RNA Polymerase Inhibitor Sales by Country (2023-2028) & (K Units)
Table 104. South America RNA Polymerase Inhibitor Revenue by Country (2017-2022) & (USD Million)
Table 105. South America RNA Polymerase Inhibitor Revenue by Country (2023-2028) & (USD Million)
Table 106. South America RNA Polymerase Inhibitor Sales by Type (2017-2022) & (K Units)
Table 107. South America RNA Polymerase Inhibitor Sales by Type (2023-2028) & (K Units)
Table 108. South America RNA Polymerase Inhibitor Sales by Application (2017-2022) & (K Units)
Table 109. South America RNA Polymerase Inhibitor Sales by Application (2023-2028) & (K Units)
Table 110. Middle East & Africa RNA Polymerase Inhibitor Sales by Region (2017-2022) & (K Units)
Table 111. Middle East & Africa RNA Polymerase Inhibitor Sales by Region (2023-2028) & (K Units)
Table 112. Middle East & Africa RNA Polymerase Inhibitor Revenue by Region (2017-2022) & (USD Million)
Table 113. Middle East & Africa RNA Polymerase Inhibitor Revenue by Region (2023-2028) & (USD Million)
Table 114. Middle East & Africa RNA Polymerase Inhibitor Sales by Type (2017-2022) & (K Units)
Table 115. Middle East & Africa RNA Polymerase Inhibitor Sales by Type (2023-2028) & (K Units)
Table 116. Middle East & Africa RNA Polymerase Inhibitor Sales by Application (2017-2022) & (K Units)
Table 117. Middle East & Africa RNA Polymerase Inhibitor Sales by Application (2023-2028) & (K Units)
Table 118. RNA Polymerase Inhibitor Raw Material
Table 119. Key Manufacturers of RNA Polymerase Inhibitor Raw Materials
Table 120. Direct Channel Pros & Cons
Table 121. Indirect Channel Pros & Cons
Table 122. RNA Polymerase Inhibitor Typical Distributors
Table 123. RNA Polymerase Inhibitor Typical Customers
List of Figures
Figure 1. RNA Polymerase Inhibitor Picture
Figure 2. Global RNA Polymerase Inhibitor Revenue Market Share by Type in 2021
Figure 3. Veliparib
Figure 4. Rucaparib
Figure 5. Talazoparib
Figure 6. Niraparib
Figure 7. Others
Figure 8. Global RNA Polymerase Inhibitor Revenue Market Share by Application in 2021
Figure 9. Hospital Pharmacies
Figure 10. Retail Pharmacies
Figure 11. Online Pharmacies
Figure 12. Global RNA Polymerase Inhibitor Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 13. Global RNA Polymerase Inhibitor Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global RNA Polymerase Inhibitor Sales (2017-2028) & (K Units)
Figure 15. Global RNA Polymerase Inhibitor Price (2017-2028) & (US$/Unit)
Figure 16. Global RNA Polymerase Inhibitor Production Capacity (2017-2028) & (K Units)
Figure 17. Global RNA Polymerase Inhibitor Production Capacity by Geographic Region: 2022 VS 2028
Figure 18. RNA Polymerase Inhibitor Market Drivers
Figure 19. RNA Polymerase Inhibitor Market Restraints
Figure 20. RNA Polymerase Inhibitor Market Trends
Figure 21. Global RNA Polymerase Inhibitor Sales Market Share by Manufacturer in 2021
Figure 22. Global RNA Polymerase Inhibitor Revenue Market Share by Manufacturer in 2021
Figure 23. RNA Polymerase Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 24. Top 3 RNA Polymerase Inhibitor Manufacturer (Revenue) Market Share in 2021
Figure 25. Top 6 RNA Polymerase Inhibitor Manufacturer (Revenue) Market Share in 2021
Figure 26. Global RNA Polymerase Inhibitor Sales Market Share by Region (2017-2028)
Figure 27. Global RNA Polymerase Inhibitor Revenue Market Share by Region (2017-2028)
Figure 28. North America RNA Polymerase Inhibitor Revenue (2017-2028) & (USD Million)
Figure 29. Europe RNA Polymerase Inhibitor Revenue (2017-2028) & (USD Million)
Figure 30. Asia-Pacific RNA Polymerase Inhibitor Revenue (2017-2028) & (USD Million)
Figure 31. South America RNA Polymerase Inhibitor Revenue (2017-2028) & (USD Million)
Figure 32. Middle East & Africa RNA Polymerase Inhibitor Revenue (2017-2028) & (USD Million)
Figure 33. Global RNA Polymerase Inhibitor Sales Market Share by Type (2017-2028)
Figure 34. Global RNA Polymerase Inhibitor Revenue Market Share by Type (2017-2028)
Figure 35. Global RNA Polymerase Inhibitor Price by Type (2017-2028) & (US$/Unit)
Figure 36. Global RNA Polymerase Inhibitor Sales Market Share by Application (2017-2028)
Figure 37. Global RNA Polymerase Inhibitor Revenue Market Share by Application (2017-2028)
Figure 38. Global RNA Polymerase Inhibitor Price by Application (2017-2028) & (US$/Unit)
Figure 39. North America RNA Polymerase Inhibitor Sales Market Share by Type (2017-2028)
Figure 40. North America RNA Polymerase Inhibitor Sales Market Share by Application (2017-2028)
Figure 41. North America RNA Polymerase Inhibitor Sales Market Share by Country (2017-2028)
Figure 42. North America RNA Polymerase Inhibitor Revenue Market Share by Country (2017-2028)
Figure 43. United States RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Canada RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Mexico RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Europe RNA Polymerase Inhibitor Sales Market Share by Type (2017-2028)
Figure 47. Europe RNA Polymerase Inhibitor Sales Market Share by Application (2017-2028)
Figure 48. Europe RNA Polymerase Inhibitor Sales Market Share by Country (2017-2028)
Figure 49. Europe RNA Polymerase Inhibitor Revenue Market Share by Country (2017-2028)
Figure 50. Germany RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. France RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. United Kingdom RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Russia RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Italy RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Asia-Pacific RNA Polymerase Inhibitor Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific RNA Polymerase Inhibitor Sales Market Share by Application (2017-2028)
Figure 57. Asia-Pacific RNA Polymerase Inhibitor Sales Market Share by Region (2017-2028)
Figure 58. Asia-Pacific RNA Polymerase Inhibitor Revenue Market Share by Region (2017-2028)
Figure 59. China RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Korea RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America RNA Polymerase Inhibitor Sales Market Share by Type (2017-2028)
Figure 66. South America RNA Polymerase Inhibitor Sales Market Share by Application (2017-2028)
Figure 67. South America RNA Polymerase Inhibitor Sales Market Share by Country (2017-2028)
Figure 68. South America RNA Polymerase Inhibitor Revenue Market Share by Country (2017-2028)
Figure 69. Brazil RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East & Africa RNA Polymerase Inhibitor Sales Market Share by Type (2017-2028)
Figure 72. Middle East & Africa RNA Polymerase Inhibitor Sales Market Share by Application (2017-2028)
Figure 73. Middle East & Africa RNA Polymerase Inhibitor Sales Market Share by Region (2017-2028)
Figure 74. Middle East & Africa RNA Polymerase Inhibitor Revenue Market Share by Region (2017-2028)
Figure 75. Turkey RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Egypt RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Saudi Arabia RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. South Africa RNA Polymerase Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Manufacturing Cost Structure Analysis of RNA Polymerase Inhibitor in 2021
Figure 80. Manufacturing Process Analysis of RNA Polymerase Inhibitor
Figure 81. RNA Polymerase Inhibitor Industrial Chain
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
Figure 83. Methodology
Figure 84. Research Process and Data Source

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

H&I Global Research

世界のRNAポリメラーゼ阻害剤市場2022年：市場規模予測（～2028年）

グローバル市場調査会社